By Elena Vardon

AstraZeneca said Monday that the phase II trial for its cancer drug Enhertu showed clinically meaningful and durable responses across patients with HER2-expressing advanced solid tumours who had been previously treated.

The Anglo-Swedish pharma giant said interim results from its DESTINY-PanTumor02 Phase 2 trial showed an objective response rate of 37.1% in the trial's overall population and also demonstrated positive antitumor activity in patients previously treated for HER2-positive metastatic colorectal cancer.

Enhertu, or trastuzumab deruxtecan, is being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

Write to Elena Vardon at elena.vardon@wsj.com

(END) Dow Jones Newswires

June 05, 2023 08:38 ET (12:38 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Ago 2023 até Set 2023 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Set 2022 até Set 2023 Click aqui para mais gráficos Astrazeneca.